| Therapeutic drug monitoring of tacrolimus-personalized therapy: second consensus report M Brunet, T Van Gelder, A Åsberg, V Haufroid, DA Hesselink, L Langman, ... Therapeutic drug monitoring 41 (3), 261-307, 2019 | 535 | 2019 |
| The role of organic anion–transporting polypeptides and their common genetic variants in mycophenolic acid pharmacokinetics N Picard, SW Yee, JB Woillard, Y Lebranchu, Y Le Meur, KM Giacomini, ... Clinical Pharmacology & Therapeutics 87 (1), 100-108, 2010 | 196 | 2010 |
| Population pharmacokinetic model and Bayesian estimator for two tacrolimus formulations – twice daily Prograf® and once daily Advagraf® JB Woillard, BCM de Winter, N Kamar, P Marquet, L Rostaing, ... British journal of clinical pharmacology 71 (3), 391-402, 2011 | 130 | 2011 |
| Population pharmacokinetics and Bayesian estimation of tacrolimus exposure in renal transplant recipients on a new once-daily formulation K Benkali, L Rostaing, A Premaud, JB Woillard, F Saint-Marcoux, S Urien, ... Clinical pharmacokinetics 49, 683-692, 2010 | 127 | 2010 |
| Personalized therapy for mycophenolate: consensus report by the international association of therapeutic drug monitoring and clinical toxicology S Bergan, M Brunet, DA Hesselink, KL Johnson-Davis, PK Kunicki, ... Therapeutic drug monitoring 43 (2), 150-200, 2021 | 124 | 2021 |
| Impact of CYP2C19 genetic polymorphisms on voriconazole dosing and exposure in adult patients with invasive fungal infections F Lamoureux, T Duflot, JB Woillard, D Metsu, T Pereira, P Compagnon, ... International journal of antimicrobial agents 47 (2), 124-131, 2016 | 97 | 2016 |
| Donor P‐gp polymorphisms strongly influence renal function and graft loss in a cohort of renal transplant recipients on cyclosporine therapy in a long‐term follow‐up JB Woillard, JP Rerolle, N Picard, A Rousseau, A Guillaudeau, ... Clinical Pharmacology & Therapeutics 88 (1), 95-100, 2010 | 82 | 2010 |
| Lessons from routine dose adjustment of tacrolimus in renal transplant patients based on global exposure F Saint-Marcoux, JB Woillard, C Jurado, P Marquet Therapeutic drug monitoring 35 (3), 322-327, 2013 | 80 | 2013 |
| Polymorphisms in type I and II inosine monophosphate dehydrogenase genes and association with clinical outcome in patients on mycophenolate mofetil O Gensburger, RHN Van Schaik, N Picard, Y Le Meur, A Rousseau, ... Pharmacogenetics and genomics 20 (9), 537-543, 2010 | 80 | 2010 |
| Sirolimus (rapamycin) for slow-flow malformations in children: the observational-phase randomized clinical PERFORMUS trial A Maruani, E Tavernier, O Boccara, J Mazereeuw-Hautier, S Leducq, ... JAMA dermatology 157 (11), 1289-1298, 2021 | 72 | 2021 |
| Risk of diarrhoea in a long‐term cohort of renal transplant patients given mycophenolate mofetil: the significant role of the UGT1A8*2 variant allele JB Woillard, JP Rerolle, N Picard, A Rousseau, M Drouet, E Munteanu, ... British journal of clinical pharmacology 69 (6), 675-683, 2010 | 68 | 2010 |
| Tacrolimus updated guidelines through popPK modeling: how to benefit more from CYP3A pre-emptive genotyping prior to kidney transplantation JB Woillard, M Mourad, M Neely, A Capron, RH Van Schaik, T Van Gelder, ... Frontiers in pharmacology 8, 358, 2017 | 66 | 2017 |
| Tacrolimus exposure prediction using machine learning JB Woillard, M Labriffe, J Debord, P Marquet Clinical Pharmacology & Therapeutics 110 (2), 361-369, 2021 | 64 | 2021 |
| Therapy response evaluation with FDG-PET/CT in small cell lung cancer: a prognostic and comparison study of the PERCIST and EORTC criteria D Ziai, T Wagner, A El Badaoui, A Hitzel, JB Woillard, B Melloni, J Monteil Cancer Imaging 13 (1), 73, 2013 | 60 | 2013 |
| Population pharmacokinetics and Bayesian estimators for refined dose adjustment of a new tacrolimus formulation in kidney and liver transplant patients JB Woillard, J Debord, C Monchaud, F Saint-Marcoux, P Marquet Clinical Pharmacokinetics 56, 1491-1498, 2017 | 51 | 2017 |
| Pharmacokinetics of mycophenolate mofetil in children with lupus and clinical findings in favour of therapeutic drug monitoring JB Woillard, B Bader‐Meunier, R Salomon, B Ranchin, S Decramer, ... British journal of clinical pharmacology 78 (4), 867-876, 2014 | 51 | 2014 |
| Impact of longitudinal exposure to mycophenolic acid on acute rejection in renal-transplant recipients using a joint modeling approach ZD Abdi, M Essig, D Rizopoulos, Y Le Meur, A Prémaud, JB Woillard, ... Pharmacological research 72, 52-60, 2013 | 48 | 2013 |
| Pharmacokinetic models to assist the prescriber in choosing the best tacrolimus dose JB Woillard, F Saint-Marcoux, J Debord, A Åsberg Pharmacological research 130, 316-321, 2018 | 45 | 2018 |
| Effect of CYP3A4*22, POR*28, and PPARA rs4253728 on Sirolimus In Vitro Metabolism and Trough Concentrations in Kidney Transplant Recipients JB Woillard, N Kamar, S Coste, L Rostaing, P Marquet, N Picard Clinical Chemistry 59 (12), 1761-1769, 2013 | 42 | 2013 |
| Estimation of drug exposure by machine learning based on simulations from published pharmacokinetic models: the example of tacrolimus JB Woillard, M Labriffe, A Prémaud, P Marquet Pharmacological research 167, 105578, 2021 | 40 | 2021 |
Nicolas Picard, PharmD, PhDProfessor of Pharmacology, University of Limoges在 unilim.fr 的电子邮件经过验证
